Clinical evaluation of Bilvadileha in the management of irritable bowel syndrome

Tiwari, Ramanand; Pandya, Darshana H; Baghel, Madhav Singh

doi:10.4103/0974-8520.127717

Cited by 9 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All bothersome symptoms should be targeted while treating these patients rather than only the predominant symptoms as suggested earlier taking into account specific IBS subtypes, symptom severity and contributing factors including psychosocial and dietary issues [63]. IBS patients with low symptom load do find significant improvement in their symptoms by use of antispasmodics [110,111], bulking agents, antidiarrheals [112,113], pro-motility agents including laxatives, [114,115] and low-FODMAP diet [42]. An outline of the management of IBS is summarized in Fig.…”

Section: Statement 20: the Initial Treatment Of Ibs Is Primarily Symp...mentioning

confidence: 99%

See 1 more Smart Citation

Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology

Ghoshal

Sachdeva

Pratap

et al. 2023

Indian J Gastroenterol

View full text Add to dashboard Cite

The Indian Neurogastroenterology and Motility Association (INMA), earlier named the Indian Motility and Functional Diseases Association developed this evidence-based practice guidelines for the management of irritable bowel syndrome (IBS). A modified Delphi process was used to develop this consensus containing 28 statements, which were concerning diagnostic criteria, epidemiology, etiopathogenesis and comorbidities, investigations, lifestyle modifications and treatments. Owing to the Coronavirus disease-19 (COVID-19) pandemic, lockdowns and mobility restrictions, web-based meetings and electronic voting were the major tools used to develop this consensus. A statement was regarded as accepted when the sum of “completely accepted” and “accepted with minor reservation” voted responses were 80% or higher. Finally, the consensus was achieved on all 28 statements. The consensus team members are of the view that this work may find use in teaching, patient care, and research on IBS in India and other nations.

show abstract

Section: Statement 20: the Initial Treatment Of Ibs Is Primarily Symp...mentioning

confidence: 99%

“…Hence, these drugs must be used with caution. Table 7 summarizes some of the studies from India on different antispasmodic drugs in the management of IBS [110,111,122,123].…”

Section: Statement 21mentioning

confidence: 99%

Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology

Ghoshal

Sachdeva

Pratap

et al. 2023

Indian J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The sangrahi characteristic of bilva is highly helpful in reducingslough and pus discharge. In addition to Bilva (Aegle marmelos), Prakshepa Dravyas in Bilvadileha include Dhanyaka ( Coriandrum sativum ) , Jiraka ( Cuminum cyminum ), Ela ( Elettaria cardamomum ), Keshara ( Crocus sativus ) , Twak ( Cinnamomum zeylanicum ) , Trikatu, Musta ( Cyperus rotundus ), and they possess such attributes as deepana, pachaka, kaphahara, vedanasthapak, and rasayana [ 21 ]. Complex medications used in ayurvedic medicine are based on the principles of antagonistic and synergistic interactions to produce the desired effects.Saptavimshati guggulu mentioned in Yogaratnakara, Bhaishajya Ratnavali and Chakradatta is widely indicated in Dusta vrana and Bhagandhara and helps in wound healing and achieving healthy granulation [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

An integrative ayurvedic approach in management of breast abscess – A case report

Jaivarshaa GV,

Dasar,

Biswas

et al. 2024

Journal of Ayurveda and Integrative Medicine

View full text Add to dashboard Cite

“…in 4 HMs were also noted ( Posadzki et al, 2013 ). Diverse different traditional medicines such as Korean medicine ( Ko et al, 2013 ), traditional Chinese medicine ( Zheng et al, 2021 ), Persian medicine ( Amini-Behbahani et al, 2019 ), Kampo (traditional Japanese herbal medicine) ( Oka et al, 2014 ) and Ayurveda ( Tiwari et al, 2013 ) reported the efficacy and safety of HM in IBS. These results are important for the discovery and development of new treatments for IBS.…”

Section: Discussionmentioning

confidence: 99%

An Overview of Systematic Reviews of Herbal Medicine for Irritable Bowel Syndrome

Jun

Kim

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Irritable bowel syndrome (IBS) is a common disorder with abdominal pain and bowel habits changes. Herbal medicines (HMs) are frequently used in the treatment of IBS. Therefore, several systematic reviews (SRs) have been conducted to assess the efficacy and safety of HM in IBS patients. This study aimed to investigate the methodology and quality of evidence of SRs, and to describe the current state of research and evidence for the treatment of IBS with HM.Methods: SRs published up to January 2022 were searched using six electronic databases. SRs and/or meta-analyses on the use of HMs for IBS were included. The effects of placebo, conventional medicine (CM), and probiotics were compared with those of HMs. Two investigators independently extracted the data and assessed methodological quality using the Measure Tool to Assessment System Reviews 2 (AMSTAR 2). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) was used to evaluate the quality of evidence for each main finding.Results: Eighteen SRs were included in this overview. Among them, eight SRs reported only specific subtypes of IBS: six SRs reported patients with diarrhea-predominant IBS, and two SRs reported patients with constipation-predominant IBS. In terms of total efficacy, HM was more effective than placebo, CM, or probiotics. HM showed a more significant effect than CM in relieving independent IBS symptom score (abdominal pain score, diarrhea score, abdominal distension score, stool frequency score, etc.) and recurrence rate. The rate of adverse events was significantly lower with HM compared to CM, and no serious adverse events were reported with HM treatment. According to AMSTAR 2, the methodological quality of the included SRs was extremely low. Furthermore, the quality of evidence for total efficacy was considered low or very low according to the GRADE tool.Conclusion: HM can be considered as an effective and safe treatment for IBS. However, the methodological quality of the included SRs and the quality of evidence was generally low. Therefore, well-designed randomized controlled trials are needed in the future so that a high-quality SR can be used to better assess the safety and efficacy of HM in the treatment of IBS.Systematic Review Registration:https://osf.io/nt6wz, identifier 10.17605/OSF.IO/NT6WZ.

show abstract

Clinical evaluation of Bilvadileha in the management of irritable bowel syndrome

Cited by 9 publications

References 5 publications

Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology

Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology

An integrative ayurvedic approach in management of breast abscess – A case report

An Overview of Systematic Reviews of Herbal Medicine for Irritable Bowel Syndrome

Contact Info

Product

Resources

About